Evofem Biosciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Evofem Biosciences generated cash of -$8,968,000, which is more than the previous year. Cash used in financing activities reached the amount of $4,776,000 last year. Net change in cash is therefore -$4,196,000.
Cash Flow
| 2014 | -9.57M | -18.07K | 81.17M |
|---|---|---|---|
| 2015 | -37.91M | -426.12K | 138.63K |
| 2016 | -16.25M | 3.1K | -10.01M |
| 2017 | -8.20M | 7.1K | 26.34K |
| 2018 | -56.5M | 2.14M | 54.41M |
| 2019 | -55.09M | -8.11M | 78.07M |
| 2020 | -104.82M | 6.22M | 154.22M |
| 2021 | -146.66M | -2.68M | 90.69M |
| 2022 | -70.41M | -341K | 63.14M |
| 2023 | -8.96M | -4K | 4.77M |
EVFM Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 4.77M | 13.58M | 72.25M | 16.62M | 1.76M | 1.70M | 11.67M | 37.74M | 75.94M | 4.36M |
Operating activities | ||||||||||
Net income | 52.97M | -76.69M | -205.19M | -142.30M | -80.03M | -125.71M | -9.99M | -13.01M | -43.15M | -10.81M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.78M | 1.01M | 1.02M | 302K | 263K | 262K | 45.87K | 69.09K | 58.42K | 17.66K |
Stock-based compensation expense | 1.18M | 3.31M | 8.89M | 12.69M | 8.57M | 17.84M | 759.32K | 1.08M | 1.57M | 612.95K |
| Deferred income tax benefit | 1.18M | 3.31M | 8.89M | 12.69M | 8.57M | 17.84M | 759.32K | 1.08M | 1.57M | 612.95K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -4.61M | 5.32M | -5.38M | -1.06M | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 2.10M | 1.56M | -21K | -6.01M | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 4.09M | 4.47M | -4K | 4.12M | -2.93M | 3.79M | 509.82K | -5.44M | 4.43M | 455.23K |
Cash generated by operating activities | -8.96M | -70.41M | -146.66M | -104.82M | -55.09M | -56.5M | -8.20M | -16.25M | -37.91M | -9.57M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | -250K | -8.23M | 0 | 0 | 0 | -200K | 0 |
Investments In Property Plant And Equipment | -4K | -341K | -2.93M | -2.25M | -164K | -7K | -6K | 0 | -226.12K | -18.07K |
Acquisitions Net | 0 | 0 | 250K | 250K | 250K | 2.15M | 250K | 0 | 0 | 0 |
Cash generated by investing activities | -4K | -341K | -2.68M | 6.22M | -8.11M | 2.14M | 7.1K | 3.1K | -426.12K | -18.07K |
Financing activities | ||||||||||
Common Stock Issued | 290K | 32.32M | 81.53M | 107.96M | 78.36M | 0 | -713K | 0 | 138.63K | 57.81M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | -157K | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -18K | -327K | -2.86M | 0 | -1.59M | 0 | 0 | 42.12M | 0 |
Repayments of term debt | 4.48M | 5.60M | 0 | -50M | -4.01M | 0 | 0 | -10.05M | 0 | -209.69K |
Cash used in financing activities | 4.77M | 63.14M | 90.69M | 154.22M | 78.07M | 54.41M | 26.34K | -10.01M | 138.63K | 81.17M |
Net Change In Cash | -4.19M | -8.81M | -58.66M | 55.62M | 14.86M | 60K | -8.16M | -26.27M | -38.19M | 71.58M |
Cash at end of period | 580K | 4.77M | 13.58M | 72.25M | 16.62M | 1.76M | 3.51M | 11.47M | 37.74M | 75.94M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |